Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT003-QbG10 in Perennial Allergic Rhinoconjunctivitis (Double-blind, Placebo-controlled Phase II)
2007-003516-62Phase 2Completed
- Sponsor
- Cytos Biotechnology AG
- Start
- Aug 2007
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) comparing CYT003-QbG10 with Placebo (2 arms). Started Aug 2007; status: completed.
02
Drugs
CYT003-QbG10
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2007-003516-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003516-62.